Galena Biopharma Inc  

(Public, NASDAQ:GALE)   Watch this stock  
Find more results for GALE
-0.21 (-9.91%)
Real-time:   3:30PM EST
NASDAQ real-time data - Disclaimer
Currency in USD
Range 1.86 - 2.15
52 week 1.56 - 7.77
Open 2.08
Vol / Avg. 4.81M/1.31M
Mkt cap 233.27M
P/E     -
Div/yield     -
EPS -0.70
Shares 121.46M
Beta 1.13
Inst. own 18%
Feb 9, 2015
Galena Biopharma Inc at Biotechnology Industry Organization CEO & Investor Conference Add to calendar
Jan 19, 2015
Galena Biopharma Inc at Noble Financial Equity Conference Add to calendar
Dec 10, 2014
Galena Biopharma Inc at Oppenheimer Healthcare Conference - 3:55PM EST - Add to calendar
Nov 19, 2014
Galena Biopharma Inc at Stifel Healthcare Conference
Nov 3, 2014
Q3 2014 Galena Biopharma Inc Earnings Call
Nov 3, 2014
Q3 2014 Galena Biopharma Inc Earnings Release
Sep 25, 2014
Galena Biopharma Inc Announces Release of Special Committee Report and Provides Abstral� (fentanyl) and NeuVaxT (nelipepimut-S) Enrollment Updates
Sep 9, 2014
Galena Biopharma Inc at Rodman & Renshaw Global Investment Conference
More events from DailyFinance »    

Key stats and ratios

Q3 (Sep '14) 2013
Net profit margin -381.05% -3083.15%
Operating margin -778.46% -1397.91%
EBITD margin - -1342.50%
Return on average assets -30.99% -107.27%
Return on average equity -83.69% -455.85%
Employees 60 -
CDP Score - -


United States - Map
+1-855-8554253 (Phone)
+1-302-6365454 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money


Galena Biopharma, Inc. (Galena), formerly RXi Pharmaceuticals Corporation, incorporated on April 3, 2006, is a biotechnology company focused on discovering, developing and commercializing therapies addressing unmet medical needs using targeted biotherapeutics. The Company is pursuing the development of cancer therapeutics using peptide-based immunotherapy products, including its main product candidate, NeuVaxTM (E75), for the treatment of breast cancer and other tumors. NeuVax is a peptide-based immunotherapy intended to reduce the recurrence of breast cancer in low-to-intermediate HER2-positive breast cancer patients not eligible for trastuzumab (Herceptin; Genentech/Roche). In January 2014, Galena Biopharma Inc acquired Mills Pharmaceuticals, which has the worldwide rights to GALE-401 (Anagrelide CR), a patented, controlled release formulation of anagrelide.

Officers and directors

Sanford J. Hillsberg J.D. Independent Chairman of the Board
Age: 65
Bio & Compensation  - Reuters
Mark W. Schwartz Ph.D. President, Chief Executive Officer
Age: 58
Bio & Compensation  - Reuters
Ryan M. Dunlap Chief Financial Officer, Vice President, Secretary
Age: 44
Bio & Compensation  - Reuters
Irving M. Einhorn Director
Age: 72
Bio & Compensation  - Reuters
William L. Ashton Independent Director
Age: 63
Bio & Compensation  - Reuters
Richard H. Chin M.D. Independent Director
Age: 47
Bio & Compensation  - Reuters
Stephen S. Galliker CPA Independent Director
Age: 67
Bio & Compensation  - Reuters
Steven A Kriegsman Independent Director
Age: 72
Bio & Compensation  - Reuters